Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis (NAPPREMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03046251
Recruitment Status : Recruiting
First Posted : February 8, 2017
Last Update Posted : October 8, 2020
Information provided by (Responsible Party):
Bianca Weinstock-Guttman, State University of New York at Buffalo

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2020
Study Completion Date : No date given